NCT03695367 - Phase 2 Herniorrhaphy Study for Opioid Elimination | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

November 20, 2018

Study Completion Date

December 15, 2018

Conditions

Postoperative Pain

Interventions

DRUG

HTX-011

HTX-011 (bupivacaine/meloxicam), 300 mg/ 9 mg via instillation.

DEVICE

Luer lock applicator

Applicator for instillation.

DEVICE

Vial access device

Device for withdrawal of drug product.

DRUG

Ibuprofen

Ibuprofen, 600 mg.

DRUG

Acetaminophen

Acetaminophen, 1 g.

DRUG

Ketorolac

Intraoperative IV ketorolac.

Trial Locations (5)

JBR Clinical Research, Draper

JBR Clinical Research, Murray

JBR Clinical Research, Salt Lake City

Lotus Clinical Research, LLC, Pasadena

Anaheim Clinical Trials, LLC, Anaheim